Adding insulin to oral antidiabetes drugs does not up CVD events

03/14/2012 | Medscape (free registration)

Data on nearly 15,000 type 2 diabetes patients revealed the odds ratio for macrovascular events associated with insulin therapy was only 0.53 in those who took one oral glucose-lowering drug, 0.85 in those who took two and 1.07 in those who took three. The findings suggest that using insulin as an add-on to OGLD treatment may not increase the incidence of cardiovascular events, researchers reported in Pharmacoepidemiology and Drug Safety.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC